Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma

Am J Clin Pathol. 2004 Dec;122(6):926-30. doi: 10.1309/C8T7-APJD-AUPR-8TLL.

Abstract

We analyzed the expression of proteases and the clinicopathologic significance in non-skull base chordoma (NSBC). By using immunohistochemical techniques, we studied the expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B (CatB), and urokinase plasminogen activator (uPA) in 29 NSBCs and compared these data with clinicopathologic parameters and the expression of cell differentiation markers. Expression of MMP-1 (P = .092), MMP-2 (P = .041), and CatB (P = .058) was associated with nuclear pleomorphism, a previously described adverse prognostic indicator. Expression of cytokeratin 8 correlated with that of MMP-1 (P = .005), MMP-2 (P = .002), and uPA (P = .032). Patients with higher MMP-2 expression had a poorer prognosis than those with lower MMP-2 expression (P = .013). We believe that NSBCs with nuclear pleomorphism or stronger epithelial character have a higher invasive ability than those without. In addition, high MMP-2 expression was an indicator of an unfavorable clinical outcome in NSBC.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / enzymology*
  • Bone Neoplasms / mortality
  • Bone Neoplasms / pathology
  • Cathepsin B / biosynthesis*
  • Chordoma / enzymology*
  • Chordoma / mortality
  • Chordoma / pathology
  • Humans
  • Immunohistochemistry
  • Keratins / metabolism
  • Matrix Metalloproteinases / biosynthesis*
  • Middle Aged
  • Prognosis
  • Survival Analysis
  • Urokinase-Type Plasminogen Activator / biosynthesis*

Substances

  • Keratins
  • Urokinase-Type Plasminogen Activator
  • Cathepsin B
  • Matrix Metalloproteinases